
1 

(1) This Order may be cited as the Misuse of Drugs (Designation) (Amendment No.2) Order (Northern Ireland) 2018 and shall come into operation on 1st November 2018.
(2) The Interpretation Act (Northern Ireland) 1954 shall apply to this Order as it applies to an Act of the Northern Ireland Assembly.
2 

(1) Schedule 1 to the Misuse of Drugs (Designation) Order (Northern Ireland) 2001 (which specifies the controlled drugs to which section 7(4) of the Misuse of Drugs Act 1971 applies) is amended as follows.
(2) In paragraph 1(a) of Part 1 —
(a) after “Cannabinol” insert “(not being the product specified in paragraph 5 (1) or (2) of Part 2 of this Schedule)”;
(b) after “Cannabinol derivatives not being dronabinol or its stereoisomers” insert “(and not being the product specified in paragraph 5(1) or (2) of Part 2 of this Schedule)”;
(c) for “Cannabis (not being the substance specified in paragraph 4 of Part 2 of this Schedule)”, substitute “Cannabis (not being the substance specified in paragraph 4 of Part 2 of this Schedule or product specified in paragraph 5(1) or (2) of Part 2 of this Schedule)”; and
(d) after “Cannabis resin” insert “(not being the product specified in paragraph 5(1) or (2) of Part 2 of this Schedule)”.
(3) In Part 2 (which specifies controlled drugs excepted from Part 1), after paragraph 4 insert—“
5. 

(1) A cannabis based product for medicinal use in humans.
(2) A product which is—
(a) specified in Part 1 as a consequence of the application of paragraphs 2 to 5 of Part 1 to a preparation or other product (not being the substance specified in paragraph 4 of Part 2) which is or contains cannabis, cannabis resin, cannabinol or a cannabinol derivative (not being dronabinol or its stereoisomers ); and
(b) produced for medicinal use in humans.
(3) In this paragraph—
 “cannabis based product for medicinal use in humans” means a preparation or other product (not being the substance specified in paragraph 4 of Part 2), which—
(a) is or contains cannabis, cannabis resin, cannabinol or a cannabinol derivative (not being dronabinol or its stereoisomers);
(b) is produced for medicinal use in humans; and
(c) is—
(i) a medicinal product, or
(ii) a substance or preparation for use as an ingredient of, or in the production of an ingredient of, a medicinal product; and
 “medicinal product” has the same meaning as in the Human Medicines Regulations 2012.
(4) In this Schedule “dronabinol” does not include any substance which—
(a) has the international non-proprietary name dronabinol (recommended by the World Health Organisation); and
(b) is derived from cannabis, cannabis resin or their constituents,
and stereoisomers of dronabinol are to be construed accordingly.”.
Sealed with the Official Seal of the Department of Health on 11th October 2018
Dr Mark Timoney
A senior officer of the
Department of Health
